Servicio de Cardiología, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, Spain; Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Pontevedra, Spain.
Unidad de Cardiología Clínica y Cuidados Agudos Cardiovasculares, Hospital Universitario Arnau de Vilanova, Lleida, Spain; Institut de Reserca Biomèdica Lleida (IRB-Lleida), Lleida, Spain. Electronic address: https://twitter.com/@PolSheperd.
Rev Esp Cardiol (Engl Ed). 2023 Jul;76(7):555-563. doi: 10.1016/j.rec.2023.01.011. Epub 2023 Mar 11.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has revealed several cardiovascular complications, including myocarditis caused by SARS-CoV-2 infection (COVID-19) or after messenger RNA vaccine administration. Because of the high prevalence of COVID-19, the expansion of vaccination programs, and the appearance of new information on myocarditis in these contexts, there is a need to condense the knowledge acquired since the start of the pandemic. To meet this need, this document was drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology, with the collaboration of the Spanish Agency for Medicines and Health Products (AEMPS). The document aims to address the diagnosis and treatment of cases of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration.
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 大流行揭示了多种心血管并发症,包括由 SARS-CoV-2 感染(COVID-19)或信使 RNA 疫苗接种后引起的心肌炎。由于 COVID-19 的高患病率、疫苗接种计划的扩大以及这些情况下心肌炎新信息的出现,有必要浓缩自大流行开始以来获得的知识。为了满足这一需求,由西班牙心脏病学会心力衰竭协会心肌炎工作组起草了这份文件,并得到了西班牙药品和保健品管理局(AEMPS)的合作。该文件旨在解决与 SARS-CoV-2 感染或信使 RNA 疫苗接种相关的心肌炎病例的诊断和治疗。